The MBA, that once-illustrious badge of business acumen, has long held a peculiar sway over boardrooms and balance sheets. It promises to transform mere mortals into "masters of the universe," armed with spreadsheets, frameworks, and an uncanny ability to speak in acronyms. Yet in industries like biotech

Drug development requires vast investments of capital and time. Even after extensive research and clinical testing, unforeseen safety problems or unexpectedly high efficacy in niche populations can dramatically alter a drug’s commercial and therapeutic trajectory. Traditional statistical methods typically focus on the mean or median response, but it is

Conformity is often the lubricant of social interaction. It smooths edges, creates predictability, and allows societies and organizations to function with a semblance of order. Yet, in fields like venture capital, biotech, and pharma, conformity often does little more than uphold mediocrity. Breakthroughs in these industries come not from towing

Louis Pasteur’s aphorism—“Chance favors only the prepared mind”—is often trotted out in the context of scientific breakthroughs or serendipitous discoveries. Yet its deeper implication isn’t just about being ready when opportunity strikes. It’s about cultivating a habit of curiosity and, crucially, asking the right questions.

Startups face an uphill battle from securing funding to navigating the labyrinth of clinical trials and regulatory approvals, the journey is as grueling as it is rewarding. Yet amid the focus on scientific discovery and regulatory hurdles, one critical aspect is often neglected: market access. Drawing on over a decade

In the quiet moments of cycling to the office, chopping vegetables for dinner, or folding a week's worth of laundry, my mind is rarely idle. These are the pockets of time when podcasts and audiobooks weave their way into my life. Played at double speed, they transform the

A few months ago, I hit a wall—hard. I’d spent years working with biopharma companies, startups, and investors, trying to help them navigate the labyrinth of European funding and regulation. But over time, I realized something unsettling: being good wasn’t enough. No matter how many introductions I

“Chance favors only the prepared mind,” observed Louis Pasteur, capturing an enduring truth about navigating an unpredictable world. At first glance, this insight champions planning and foresight, yet its deeper resonance lies in the interplay between preparation and action. Pasteur’s wisdom reminds us that readiness isn’t about knowing

Annoyance is humanity’s most underappreciated emotion. It’s a prickly, uncomfortable feeling that demands attention—your brain’s way of saying, “This could be better.” While some dismiss it as unproductive grumbling, annoyance, when properly wielded, becomes a razor-sharp tool for improvement. My own annoyance with atrocious pitch

Total Addressable Market (TAM) is a ubiquitous metric in biotech investment pitches, used to quantify the theoretical revenue potential of novel therapies. Its simplicity and apparent rigor make it an appealing tool for startups seeking to attract investors. At its core, TAM promises a snapshot of market opportunity, assuming full